Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
PLUS THERAPEUTICS, Inc. (PSTV)
Company Research
Source: GlobeNewswire
HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13th, 2026. Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutical, diagnostics, and medical device sectors. He has led the development of payer engagement strategies, health technology assessment (HTA) dossiers, and value frameworks supporting product launches and commercialization for leading healthcare organizations. “Randy brings a rare combination of dee
Show less
Read more
Impact Snapshot
Event Time:
PSTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSTV alerts
High impacting PLUS THERAPEUTICS, Inc. news events
Weekly update
A roundup of the hottest topics
PSTV
News
- Plus Therapeutics regains compliance with Nasdaq [Seeking Alpha]Seeking Alpha
- Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire
- Plus Therapeutics (PSTV) had its price target lowered by Ascendiant Capital Markets from $475.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
- Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical PipelineGlobeNewswire
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant GliomasGlobeNewswire
PSTV
Earnings
- 8/14/25 - Beat
PSTV
Sec Filings
- 4/21/26 - Form 3
- 4/21/26 - Form 8-K
- 4/9/26 - Form 8-K
- PSTV's page on the SEC website